Antiallergic drug Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist

Type 2 diabetes mellitus (T2DM) is a chronic disease with hallmarks of hyperglycemia and hyperlipidemia. Long-term hyperglycemia damages the functions of multiple tissues and organs leading to a series of complications and disability or even death. Nuclear receptor farnesoid X receptor (FXR) antagonism has been recently discovered to exhibit beneficial effect on glucose metabolism in T2DM mice, although the underlying mechanisms remain unclear. Here, we performed the study on the discovery of new FXR antagonist and investigated the mechanism underlying the amelioration of FXR antagonism on glucose homeostasis in T2DM mice by using the determined FXR antagonist as a probe.

Source: Metabolism - Clinical and Experimental - April 4, 2021 Category: Biomedical Science Authors: Tong Zhao, Jie Wang, Yidi Chen, Shan Wang, Jian Lu, Jianlu Lv, Shiliang Li, Jiaying Wang, Minyi Qian, Honglin Li, Xu Shen Source Type: research